Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsClausen, Frederik Banch
Barrett, Angela Natalie
Akkok, Cigdem Akalin
Bergstrom, Karolina Danielsson
Boggione, Carolina Trucco
Baevre, Mette Silihagen
Drnovsek, Tadeja Dovc
de Haas, Masja
Halldorsdottir, Anna Margret
Al Houghton, Jayne
Jakobsen, Marianne Antonius
Kvitland, Mona Andersen
Legler, Tobias J.
Olsson, Martin L
Sachs, Ulrich J
van der Schoot, Ellen
Sorensen, Anne Solling
Dziegiel, Morten Hanefeld
MetadataShow full item record
CitationNoninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop. 2019, 114(4):386-393 Vox Sang
AbstractBACKGROUND AND OBJECTIVES: Fetal RHD genotyping of cell-free fetal DNA from RhD-negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 28 laboratories. MATERIALS AND METHODS: Aliquots of pooled maternal plasma were sent to each laboratory. One sample was positive, and the second sample was negative for fetal RHD, verified by pre-workshop testing using quantitative real-time PCR (qPCR) analysis of RHD exons 4, 5, 7 and 10. Plasma samples were shipped at room temperature. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. Different methodological approaches were used, all employing qPCR with a total of eight different combinations of RHD exon targets. The samples were tested blindly. RESULTS: Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD-positive sample, and four inconclusive results were reported for the RHD-negative sample. All clinical conclusions were satisfactory. CONCLUSION: This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- External quality assessment of noninvasive fetal RHD genotyping.
- Authors: Clausen FB, Hellberg Å
- Issue date: 2020 Jul
- Determination of fetal RHD type in plasma of RhD negative pregnant women.
- Authors: Sørensen K, Kjeldsen-Kragh J, Husby H, Akkök ÇA
- Issue date: 2018 Sep
- Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
- Authors: Haimila K, Sulin K, Kuosmanen M, Sareneva I, Korhonen A, Natunen S, Tuimala J, Sainio S
- Issue date: 2017 Oct
- Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis.
- Authors: Clausen FB, Rieneck K, Krog GR, Bundgaard BS, Dziegiel MH
- Issue date: 2019
- Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
- Authors: Tiblad E, Taune Wikman A, Ajne G, Blanck A, Jansson Y, Karlsson A, Nordlander E, Holländer BS, Westgren M
- Issue date: 2013